Actavis announces new members of the board of directors

Actavis, a pharmaceutical company, announced today that two former members of the Allergan board of directors, Michael R. Gallagher and Peter J. McDonnell, have been named to the Actavis board of directors.

David E.I. Pyott, chairman and CEO of Allergan, has chosen not to join the combined company’s board of directors. Pyott will still serve as chairman of The Allergan Foundation.

"I am pleased that Michael and Peter will be joining the board of the combined company,” Pyott said. “Their exceptional qualifications – in particular Michael's nearly two decades on the Allergan Board and Peter's leading stature in Ophthalmology – have been valuable contributors to Allergan's tremendous achievements during the last several years and will be critical in ensuring the continued success of the new company going forward."

In addition to Gallagher and McDonnell, the Actavis board of directors includes Executive Chairman Paul Bisaro, CEO and President Brenton Saunders, Catherine Klema, Nesli Basgoz, James Bloem, Christopher Bodine, Christopher Coughlin, Patrick O'Sullivan, Ronald Taylor and Fred Weiss.

In preparation for the closing of the acquisition of Allergan, the Actavis board of directors voted on Feb. 5 to reduce the board from 14 members down to 12. Tamar Howson, John King, Jiri Michal and Andrew Turner voluntarily resigned, effective at the close of the transaction.